Cargando…
2018–2019 Drug Updates in Hematologic Malignancies
Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and...
Autor principal: | Held, Lauren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857325/ https://www.ncbi.nlm.nih.gov/pubmed/33598320 http://dx.doi.org/10.6004/jadpro.2020.11.3.7 |
Ejemplares similares
-
2019–2020 Drug Updates in Hematologic Malignancies
por: Finnes, Heidi D.
Publicado: (2021) -
2020–2021 Drug Updates in Hematologic Malignancies
por: Hanna, Kirollos
Publicado: (2022) -
2021–2022 Drug Updates in Hematologic Malignancies
por: Tobin, Jenni
Publicado: (2023) -
2018–2019 Drug Updates in Solid Tumors
por: Barbour, Sally
Publicado: (2020) -
New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
por: Harvey, R. Donald
Publicado: (2018)